Over the past 3 months, 7 analysts have published their opinion on Iovance Biotherapeutics IOVA stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

These 7 analysts have an average price target of $23.14 versus the current price of Iovance Biotherapeutics at $5.53, implying upside.

Below is a summary of how these 7 analysts rated Iovance Biotherapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This average price target has increased by 40.24% over the past month.

Stay up to date on Iovance Biotherapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.